On July 30, MSD announced its H1 2024 performance, with total revenue of $31.887 billion, representing an 8% year-over-year increase. MSDPharmaceutical business revenue was $28.415 billion, a year-on-year increase of 9%, of which revenue in China was $3.534 billion.Accounting for 12.4% of MSD's global market shareR&D investment was $7.492 billion, a year-on-year decrease of 57%.In the first half of 2024, the sales of the "blockbuster drug" Keytruda (Pembrolizumab) continued to break records, achieving revenue of $14.217 billion with an 18% growth rate. With this double-digit high growth, Keytruda may create a sales record of $30 billion this year. The remarkable sales performance fully reflects the effectiveness of the product development strategy, especially Merck Sharp & Dohme AG's extensive layout in indications.In June this year, K drug received its 40th approval in the US, combinedStandard chemotherapy treats patients with primary advanced or recurrent endometrial cancer. This means that Keytruda (K药) becomesThe First in the Field of Endometrial CancerRegardless of Mismatch Repair StatusFirst-line immunotherapy, this is alsoK drug inEndometrial Cancer FieldThe third approved indication.
Building on Keytruda, MSD has also developedMK-7684A Compound (Pembrolizumab + TIGIT antibody Vibostolimab). Notably,MSD announced in May that it will terminate the ongoing MK-7684A adjuvant treatment following surgical resection.Stage IIB-IVPhase III KeyVibe-010 Study in High-Risk Melanoma Patients.The reason is that the studyIn a pre-planned analysisMet the criteria for futility.HPV Vaccine Gardasil/Gardasil 9 Sales Reach $4.727 Billion, Up 7% Year-over-Year. The product'sThe growth was primarily driven by improved pricing, demand, and public sector procurement patterns in the U.S., as well as increased demand in certain markets outside the U.S.Notably, sales in the Chinese market declined compared to the same period last year due to shipment timing, largely offsetting growth.MSD's leadership position in the HPV vaccine sector is quite solid. However, as strong as MSD is, it must also consider the future.More intense iterative competition in HPV vaccines.In response, MSD has taken action. In March this year, MSD announced plans to initiate a clinical study on a multivalent HPV vaccine, aiming to provide protection against a broader range of HPV types. Meanwhile, MSD also proposed to explore the efficacy and safety of a single-dose regimen for the nine-valent HPV vaccine (Gardasil 9) compared to the three-dose regimen.Products in the oncology field Welireg (HIF-2α inhibitor) and Reblozyl (Luspatercept), antiCytomegalovirus Infection Drug Prevymis(Letermovir), and15-Valent Pneumococcal Vaccine Vaxneuvance (V114)Sales growth was in the double digits or higher, bringing in a significant amount of incremental revenue.MSD's Main Product Sales in the First Half of 2024 (USD billion)
Sales of the 23-valent pneumococcal vaccine Pneumovax 23 continued to plummet, reaching only $120 million, a 36% decline, making it one of the products with the most severe sales drops in MSD's financial report.On the pneumococcal vaccine track, MSD and Pfizer are engaged in a fierce battle, with the latter possessingPrevnar series products.This year, MSD has intensified its efforts,Its 21-valent pneumococcal conjugate vaccine Capvaxive (V116) was approved for marketing by the FDA in June, becoming the first pneumococcal conjugate vaccine specifically designed for adults.。Not justPneumococcal Vaccine Track, MSD has a new generation of products in many niche fields to strengthen its product moat. For example,In the cardiovascular field,Following Adempas ($142 million, +14%), another new pulmonary arterial hypertension drug, Winrevair, successfully entered the U.S. market in March this year. Within just a few months, it generated $70 million in revenue, marking a strong start.WinrevairPriced at $14,000 per vial, administered every 3 weeks per vial.The frequency is 242,000 USD/year. In the second quarter, more than 2000 patients have receivedWinrevair has been prescribed, and more than 1,000 patients have started treatment.In the field of virology, MSD also welcomed new progress this month.Clesrovimab（MK-1654）PreventionRespiratory Syncytial Virus (RSV) InfectionPhase IIb/III MK-1654-004 Study Achieves Positive Results, Moving One Step Closer to Market.In the metabolic field, the market shares of two products for treating type 2 diabetes, Januvia and Janumet, continue to shrink.Given the strong global demand for key growth products, particularly oncology products, MSD has raised its full-year sales outlook, with expected revenue reaching $63.4-64.4 billion, representing a year-over-year increase of 5-7%. DespiteThe reduction in sales volume of the GARDASIL vaccine at market vaccination sites handled by Zhifei Biological did have some impact on performance.Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
